Super Hi International Holding LTD. - ADR (HDL) Stock Price

17.867 +0.00 (+0.00%)
Open: 17.867 Vol: 0 Day's range: 17.867 - 17.867 Nov 12, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
HDL Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL BUY SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 17.71▲ 17.71▲ 17.71▲ 17.58▲ 17.66▲
MA10 17.85▼ 17.94▼ 17.94▼ 17.41▲ 18.05▼
MA20 18.28▼ 18.49▼ 18.53▼ 17.64▲ 18.80▼
MA50 19.07▼ 19.33▼ 19.42▼ 18.21▼ 21.43▼
MA100 20.00▼ 21.32▼ 21.46▼ 18.91▼ N/A    
MA200 22.42▼ 22.88▼ 23.16▼ 20.71▼ N/A    
  5 mins 30 mins Hourly Daily Weekly
MACD 0.013▲ -0.004▼ -0.003▼ 0.091▲ -0.099▼
RSI 43.251▼ 42.760▼ 42.849▼ 51.540▲ 43.261▼
STOCH 50.780     43.329     43.329     77.020     20.670    
WILL %R -41.696     -51.183     -51.183     -0.026▲ -68.055    
CCI -37.539     -59.163     -59.163     132.261▲ -69.068    
Latest Filters Detected On HDL
CDL $HDL Doji Candlestick Pattern Detected Set Alert
Super Hi International Holding LTD. - ADR News
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
Wednesday, November 12, 2025 08:01 AM
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment ...
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 ...
Wednesday, November 12, 2025 08:01 AM
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial demonstrating that treatment ...
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug
Monday, November 10, 2025 09:37 AM
Ionis' olezarsen cut triglycerides by up to 72% and reduced acute pancreatitis events by 85% in Phase 3 studies of severe hypertriglyceridemia.
HDL historical stock data
date open high low close volume
12/11/25 17.867 17.867 17.867 17.867 0
11/11/25 17.867 17.867 17.867 17.867 0
10/11/25 17.25 17.8674 17.25 17.8674 632
07/11/25 16.81 17.00 16.81 17.00 728
06/11/25 17.30 17.30 17.30 17.30 568
05/11/25 16.3001 16.52 16.3001 16.52 1,445
04/11/25 17.43 17.43 17.43 17.43 0
03/11/25 17.43 17.43 17.43 17.43 0
31/10/25 17.43 17.43 17.43 17.43 0
30/10/25 17.43 17.43 17.43 17.43 0
Quote Details
52wk Low:15.575
52wk High:30.00
Vol:0
Avg Vol(3m):28.7K
1Y Chng:+8.42%
1M Chng:-4.91%
Add to Watch List
More Information
Index US Composite
Market Cap. 1.05B